Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

Benjamin P. Sablan; Dong Joon Kim; Nina G. Barzaga; Wan Cheng Chow; Mong Cho; Sang Hoon Ahn; Seong Gyu Hwang; Ji Hyun Lee; Hamid Namini; William L. Heyward

doi:10.1016/j.vaccine.2012.02.001

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

Benjamin P. Sablan, Dong Joon Kim, Nina G. Barzaga, Wan Cheng Chow, Mong Cho, Sang Hoon Ahn, Seong Gyu Hwang, Ji Hyun Lee, Hamid Namini, William L. Heyward

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

48 Citations (Scopus)

Abstract

Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B^®). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.

Original language	English
Pages (from-to)	2689-2696
Number of pages	8
Journal	Vaccine
Volume	30
Issue number	16
DOIs	https://doi.org/10.1016/j.vaccine.2012.02.001
Publication status	Published - 2012 Mar 30

Bibliographical note

Funding Information:
Funding for this study was provided by Dynavax Technologies Corporation , Berkeley, California. Editorial assistance in manuscript preparation was provided by Amy M. Horton, PharmD, of The JB Ashtin Group, Inc.

All Science Journal Classification (ASJC) codes

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2012.02.001

Cite this

Sablan, B. P., Kim, D. J., Barzaga, N. G., Chow, W. C., Cho, M., Ahn, S. H., Hwang, S. G., Lee, J. H., Namini, H., & Heyward, W. L. (2012). Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine, 30(16), 2689-2696. https://doi.org/10.1016/j.vaccine.2012.02.001

@article{7753d5af86844e45a02dea95ed8f2f20,

title = "Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine",

abstract = "Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B{\textregistered}). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.",

author = "Sablan, {Benjamin P.} and Kim, {Dong Joon} and Barzaga, {Nina G.} and Chow, {Wan Cheng} and Mong Cho and Ahn, {Sang Hoon} and Hwang, {Seong Gyu} and Lee, {Ji Hyun} and Hamid Namini and Heyward, {William L.}",

note = "Funding Information: Funding for this study was provided by Dynavax Technologies Corporation , Berkeley, California. Editorial assistance in manuscript preparation was provided by Amy M. Horton, PharmD, of The JB Ashtin Group, Inc. ",

year = "2012",

month = mar,

day = "30",

doi = "10.1016/j.vaccine.2012.02.001",

language = "English",

volume = "30",

pages = "2689--2696",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "16",

}

TY - JOUR

T1 - Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

AU - Sablan, Benjamin P.

AU - Kim, Dong Joon

AU - Barzaga, Nina G.

AU - Chow, Wan Cheng

AU - Cho, Mong

AU - Ahn, Sang Hoon

AU - Hwang, Seong Gyu

AU - Lee, Ji Hyun

AU - Namini, Hamid

AU - Heyward, William L.

N1 - Funding Information: Funding for this study was provided by Dynavax Technologies Corporation , Berkeley, California. Editorial assistance in manuscript preparation was provided by Amy M. Horton, PharmD, of The JB Ashtin Group, Inc.

PY - 2012/3/30

Y1 - 2012/3/30

N2 - Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B®). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.

AB - Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B®). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.

UR - http://www.scopus.com/inward/record.url?scp=84862785552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862785552&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.02.001

DO - 10.1016/j.vaccine.2012.02.001

M3 - Article

C2 - 22342916

AN - SCOPUS:84862785552

SN - 0264-410X

VL - 30

SP - 2689

EP - 2696

JO - Vaccine

JF - Vaccine

IS - 16

ER -

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this